Aclarion vs Advanced Biomed
ACON and ADVB side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACON and ADVB compare
Aclarion is the larger company, worth 1.2 times as much as Advanced Biomed ($4.7M against $3.8M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACON | ADVB |
|---|---|---|
| Size and price | ||
| Market cap | $4.7M | $3.8M |
| Share price | $1.63 | $2.32 |
| Change, 1 year | −77.5% | −71.5% |
| Beta (5Y) | 0.77 | 0.73 |
| Employees | 11 | 12 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.4× |
| P/S | 47.7× | – |
| P/B | 0.3× | 0.3× (better) |
| Growth | ||
| Revenue growth (TTM) | 46.0% | – |
| Profitability | ||
| Gross margin | 29.1% | – |
| Operating margin | −10789% | – |
| Net margin | −10260% | – |
| Return on equity | −74.1% | 84.8% (better) |
| Return on invested capital | −959% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.17 (better) | 9.33 |
| Altman Z-score | −4.34 | 1.35 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −33.4% | −6.5% (better) |
| Shareholder yield | −33.4% | −6.5% (better) |
| Ownership | ||
| Held by institutions | 9.0% | – |
| Held by insiders | 16.4% | 0.00% |
| Insider net buying, 12 months | $177K | – |
| Short interest, % of float | – | 0.68% |
Go deeper
- ACON stock overview
- ACON income statement
- ACON valuation and score
- ADVB stock overview
- ADVB income statement
- ADVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.